CStone Pharmaceuticals
HKEX:2616

Watchlist Manager
CStone Pharmaceuticals Logo
CStone Pharmaceuticals
HKEX:2616
Watchlist
Price: 2.36 HKD 2.61%
Market Cap: 3B HKD
Have any thoughts about
CStone Pharmaceuticals?
Write Note

CStone Pharmaceuticals
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CStone Pharmaceuticals
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
CStone Pharmaceuticals
HKEX:2616
Long-Term Investments
ÂĄ12.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Long-Term Investments
ÂĄ635.2m
CAGR 3-Years
25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Long-Term Investments
ÂĄ2.3B
CAGR 3-Years
270%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Long-Term Investments
ÂĄ1.4B
CAGR 3-Years
89%
CAGR 5-Years
126%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Long-Term Investments
ÂĄ295.2m
CAGR 3-Years
6%
CAGR 5-Years
24%
CAGR 10-Years
39%
Imeik Technology Development Co Ltd
SZSE:300896
Long-Term Investments
ÂĄ1.9B
CAGR 3-Years
216%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CStone Pharmaceuticals
Glance View

Market Cap
3B HKD
Industry
Biotechnology

Cstone Pharmaceuticals Co. Ltd. engages in the research and development of highly complex biopharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 264 full-time employees. The company went IPO on 2019-02-26. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The firm conducts its businesses mainly in domestic market.

Intrinsic Value
2.92 HKD
Undervaluation 19%
Intrinsic Value
Price

See Also

What is CStone Pharmaceuticals's Long-Term Investments?
Long-Term Investments
12.7m CNY

Based on the financial report for Jun 30, 2024, CStone Pharmaceuticals's Long-Term Investments amounts to 12.7m CNY.

What is CStone Pharmaceuticals's Long-Term Investments growth rate?
Long-Term Investments CAGR 1Y
251%

Over the last year, the Long-Term Investments growth was 251%.

Back to Top